Skip to content
Screener

Net Change in Cash at other companies

Eli Lilly logo
Eli LillyLLY
$3.67B+1,196%
Aardvark Therapeutics, Inc. logo
Aardvark Therapeutics, Inc.AARD
$15.39M+144%
Viking Therapeutics logo
Viking TherapeuticsVKTX
-$47.71M-524%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
$5.82M-64.4%
TG Therapeutics logo
TG TherapeuticsTGTX
$40.38M+1,446%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
-$446.5M-1,048%

Other financials

Income statement

See full
Revenue$60.1M+83.8%
Gross profit$53.0M+82.3%
Operating income-$52.4M-11.4%
Net income-$55.6M-12.4%
EPS (diluted)-$0.83-2.5%

Balance sheet

See full
Cash & equivalents$62.1M-41.4%
Total debt$112.3M-1.1%
Total equity$122.9M+549%
Total assets$442.3M+14.4%

Cash flow

See full
Operating cash flow-$44.2M-9.5%
CapEx$238.3K
Free cash flow-$29.2M-2.4%

Valuation

See full
Market cap$7.62B+27.5%
Enterprise value$7.67B+28.8%
P/S35.1×-3.2×

Profitability

See full
Gross margin89.4%-0.2pp
Operating margin-90.9%-19.8pp
Net margin-93.3%-18.2pp
FCF margin-61.5%-14.1pp

Returns & leverage

See full
Return on equity-285.8%-68.9pp
Debt / equity0.9×-5.1×
Current ratio4.2×+0.9×

Where this comes from

Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The source filing: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-030549
Line itemThree months ended March 31, 2026Three months ended March 31, 2025
Proceeds from ATM equity offering34,034
Net cash (used in) provided by financing activities(5,400)32,499
Effect of exchange rates on cash448(2)
Net increase in cash, cash equivalents and restricted cash7,91516,958
Cash, cash equivalents and restricted cash at beginning of period54,82389,601
Cash, cash equivalents and restricted cash at end of period$62,738$106,559
Supplemental disclosure of non-cash investing and financing activities:
Accretion of preferred stock dividends$1,104$1,322

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Rhythm Pharmaceuticals, Inc.'s net change in cash?
Rhythm Pharmaceuticals, Inc. (RYTM) reported net change in cash of $7.92M in Q1 2026.
How has Rhythm Pharmaceuticals, Inc.'s net change in cash changed year-over-year?
Rhythm Pharmaceuticals, Inc.'s net change in cash decreased by 53.3% year-over-year, from $16.96M to $7.92M.
What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s net change in cash?
Over 2 years (2023 to 2025), Rhythm Pharmaceuticals, Inc.'s net change in cash has grown at a -29.2% compound annual growth rate (CAGR), from -$73.62M to -$36.85M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

Ask your AI about Rhythm Pharmaceuticals, Inc.'s net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude